DailyIQ
|
Sector:HealthcareAll sectors
Last updated 14 minutes ago

A·Agilent Technologies, Inc.

$.
-. (-.%)
High
$136.06
Open
$136.06
Market Cap
38.25B
52W High
$160.27
Low
$136.00
P. Close
$138.37
P/E
27.05
52W Low
$108.35
Fwd P/E
90.74
DailyIQ Est.
$173.30
Technical Score (1D)
82
BUY
News Sentiment
76
BULLISH
Agilent Technologies just announced a new enterprise‑wide AI partnership with OpenAI and Boston Consulting Group, a move that could embed advanced machine‑learning capabilities across its instruments, software, and customer workflows. The company also lifted its full‑year 2026 revenue guidance to $7.39–7.49 billion, reflecting stronger‑than‑expected sales and earnings in late May and early June. The AI collaboration is expected to accelerate product development and differentiation, especially in the diagnostics and analytical instrumentation segments where Agilent recently launched several new offerings. These developments suggest a more robust growth trajectory for the next 1–10 trading days, as the company positions itself to capture a larger share of the life‑sciences market. The raised guidance signals confidence in continued demand for Agilent’s core products, which could buoy investor sentiment and support the stock’s valuation. The integration of AI may also improve operational efficiencies and reduce time‑to‑market for new instruments, potentially translating into higher margins. Traders should monitor the upcoming earnings release for any further updates to guidance and for details on the progress of the AI partnership. Additionally, watch for announcements of new product launches that incorporate the AI capabilities, as these could validate the partnership’s impact. Finally, keep an eye on any regulatory or supply‑chain developments that could affect the deployment of AI‑enhanced diagnostics in the near term.
Earnings Summary
Agilent Technologies is a global provider of application‑focused solutions for the life sciences, diagnostics, and applied chemical markets, operating through Life Sciences and Diagnostics, Agilent CrossLab, and Applied Markets segments that supply advanced instrumentation, services, and analytical products. In the diagnostics and research sector, Agilent has maintained a multi‑channel distribution strategy that supports broad market access. Recent quarterly performance shows that the company beat earnings estimates in six of the last seven quarters, with Q4 2024 EPS of $1.31 versus an estimate of $1.27 and revenue of $1.681 billion, and Q1 2025 EPS of $1.31 versus $1.26 and revenue of $1.668 billion. In the most recent two quarters, Q1 2026 EPS of $1.36 fell short of the $1.396 estimate while revenue dipped to $1.798 billion, but Q2 2026 EPS rose to $1.49 beating the $1.435 estimate and revenue climbed to $1.835 billion, reflecting a 5% revenue increase and a 9% EPS gain versus Q2 2025. Historically, Agilent has shown a consistent pattern of EPS beats with revenue growth that has accelerated through Q3 2025, then experienced a modest dip in Q1 2026 before rebounding in Q2 2026, indicating resilience in earnings even when revenue fluctuates. Recent news highlights an enterprise‑wide AI partnership with OpenAI and Boston Consulting Group, a move that could embed machine‑learning capabilities across instruments and software, and the company’s lift of full‑year 2026 revenue guidance to $7.39‑$7.49 billion, signaling confidence in continued demand. Forward‑looking watch points include monitoring the progress of the AI collaboration, any updates to guidance following the partnership, and the impact of new product launches that incorporate AI, as well as potential regulatory or supply‑chain developments that could affect deployment of AI‑enhanced diagnostics.

EPS

EstBeatMiss
$1.22$1.32$1.43$1.53$1.64Q1'25Q2'25Q3'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.49 - -
Q2'26$1.44$1.49+3.8%
Q1'26$1.40$1.36-2.6%
Q3'25$1.58$1.59+0.4%
Q2'25$1.37$1.37+0.2%
Q1'25$1.26$1.31+3.6%

Revenue

EstBeatMiss
$1.6B$1.7B$1.8B$1.8B$1.9BQ1'25Q2'25Q3'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.9B - -
Q2'26$1.8B$1.8B+0.0%
Q1'26$1.8B$1.8B-2.4%
Q3'25 - $1.9B -
Q2'25 - $1.7B -
Q1'25 - $1.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

A Stock Snapshot

A is currently trading at $135.44, giving Agilent Technologies, Inc. a market cap of 38.25B and a P/E ratio of 27.1. Today's range spans $136.00–$136.06, with shares opening at $136.06 and moving down $2.93 (2.1%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 76/100.

Over the past year A has traded between $108.35 and $160.27 - the current price is +25.0% off the 52-week low and -15.5% from the high. 30 analysts cover the stock with a Buy consensus and a mean 12-month target of $161.00 (range $144.00–$185.00), implying upside of +18.9%.

The Healthcare sector has plenty of names, but A is one of the few right now where technical and sentiment data are both bullish. Score: 82/100 (BUY). Sentiment: bullish (76/100). Price: $135.44 (in the middle of its 52-week range). The current P/E ratio stands at 27.1. With 38.25B in market cap, this is the scale where fundamental thesis and technical setup reinforce rather than compete with each other. Annual range: $108.35–$160.27.

What makes A's BUY setup (82/100) particularly actionable at 38.25B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $135.44 (in the middle of its 52-week range in $108.35–$160.27), with sentiment running bullish at 76/100, the setup rewards conviction-sized positioning more than it does speculative small bets.